|Articles|March 20, 2012

Patient Centricity

Articles, news, blogs, videos that include topics that put the patient first in clinical trials.

Subjects Wants Results
This blog interview with Joseph Kim, Director of Clinical Operations at Shire, offers his take when he mediated a patient panel focused on their experiences participating in a clinical trial at the CBI Patient Centricity Forum.

Providing Results to Volunteers
This peer-review article from CISCRP also discusses clinical trial results for participants in the form of a survey.

Direct-to-Patient Enrollment Strategies
This peer-review article discusses the results of an online outreach campaign for participant enrollment in a clinical trial, versus other recruitment techniques.

Pfizer’s REMOTE Trial Experience

Bringing Trials to the Patient at Home

Trials By Bus

Social Media Patient Recruitment Success

Thomas Krohn of Lilly Center of Innovation Discusses Patient CentricitySmart Trials, Smarter PatientsExisting Clinical Trial Infrastructure Reveals Alarming Behaviors from Research ParticipantsA New Look at Global Study Volunteer Experiences with Informed ConsentImperatives to Share Trial Results with VolunteersPatient Centric Clinical Research: A Renaissance in the MakingRe-Imagining Clinical Trial Info in a Patient-Centric WayPatient First Approach to Improve Oncology Trials

The Meaning of Patient Centricity

Exisiting Clinical Trials Infrastructure Reveals Alarming Behaviors from Research Subjects

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

October 2nd, 2026

What ClinOps Professionals Just Starting With AI Should Keep Top of Mind

In this video interview, Claire Riches, VP of clinical solutions at Citeline, offers practical guidance for clinical operations teams beginning their AI journey—making the case that the tools are more accessible than many assume and that waiting to start is a competitive risk in itself.

October 2nd, 2026

ACT Brief: Proactive Trial Risk Management, Federal Infrastructure Modernization, Pediatric Heart Disease Treatment

In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.

© Tada Images - © Tada Images - stock.adobe.com

October 1st, 2026

HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure

The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.

October 1st, 2026

What an AI-Informed Approach Means for How Sponsors Think About Risk

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.

October 1st, 2026

ACT Brief: AI as Design Advisor, Autonomous Agent Governance, Oral Weight-Loss Therapy Switch

In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.

September 30th, 2026

The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials

AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.

September 30th, 2026

Where AI Leads in Trial Design—and Where Humans Still Need To

In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.

September 30th, 2026

ACT Brief: Enrollment Feasibility Pressure-Testing, RWE Infrastructure Gaps, and Peptide Rulemaking Standstill

In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.